EU Centralised Authorisation of BioNet’s Pertussis‑Only Vaccine

Medicines intended for use across the European Union may be assessed through the centralised authorisation procedure coordinated by the European Medicines Agency. BioNet pertussis-only vaccine was evaluated under this framework to ensure a harmonised scientific assessment applicable to all EU Member States.

The centralised procedure involves a comprehensive review of quality, non-clinical, and clinical data by the Committee for Medicinal Products for Human Use. The CHMP evaluates the benefit–risk balance of the vaccine based on evidence generated during its development programme.

Following the CHMP’s positive opinion, the European Commission grants a single Marketing Authorisation that is valid throughout the EU. This approach ensures consistent regulatory standards and supports equal access to authorised vaccines across Member States.

The CHMP’s centralised scientific review confirmed that BioNet’s pertussis‑only vaccine meets EU expectations for manufacturing quality, clinical outcome data, and safety surveillance. Post‑authorisation requirements, including pharmacovigilance activities, remain integral to its lifecycle management.

The use of the centralised procedure reflects the public health relevance of pertussis prevention and supports coordinated regulatory decision-making at the European level.

#pertussis-only #Vaccines #EMA #EU #booster #PTgen #PublicHealth #Pertussis #Biotechnology

Read the full news: VacPertagen Receives EU Approval